

Special Issue

Vaccines in Veterinary Medicine

Message from the Guest Editors

Many emerging and re-emerging diseases are significant global threats to animal and public health. As the most effective means of epidemic prevention and control, the development of the vaccine has attracted much attention. From traditional vaccines to genetically engineered vaccines based on DNA recombination technology such as subunit vaccines, live vector vaccines, transgenic plant vaccines, and third-generation vaccines, they play an important role in curbing the spread of animal diseases. We are pleased to invite you to share the latest progress on animal vaccines. This Special Issue aims to systematically solicit new progress, new technology, and new achievements in various animal vaccines. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: vaccine-induced immunity, species-specific immunogen design and discovery, and vaccine epidemiology and economics, which will provide a reference for the comprehensive prevention of animal diseases. Criteria for acceptance of an article are innovativeness, clarity, novelty, and relevance to the journal's scope.

Guest Editors

Dr. Jun Li
Dr. Jianli Shi
Dr. Chen Li

Deadline for manuscript submissions

closed (1 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/154502

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).